Physician profile
Arthur L Malkani
NPI 1063444107
$9,617,365.12
in general payments reported to CMS, 2019-2025
38 companies · $1.9M in 2025
The $1.9M reported for 2025 was more than what 99% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1.2M · 2020: $1.1M · 2021: $1.2M · 2022: $1.2M · 2023: $1.4M · 2024: $1.7M · 2025: $1.9M.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $4.8M · Consulting Fee: $107K · Travel and Lodging: $55K · Food and Beverage: $15K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $4,793,630.38 |
| Consulting Fee | $106,875.00 |
| Travel and Lodging | $54,595.94 |
| Food and Beverage | $14,942.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $9,610,140.85 | 2019-2025 | Reunion, Triathlon, Accolade |
| Pacira Therapeutics, INC. | $1,747.43 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $1,232.98 | 2019-2025 | Euflexxa |
| Melinta Therapeutics, LLC | $456.22 | 2019-2023 | Orbactiv, Kimyrsa |
| Pacira Pharmaceuticals Incorporated | $423.00 | 2022-2025 | Zilretta, Exparel, Iovera |
| Smith+Nephew, INC. | $312.34 | 2019-2025 | Pico 7, Renasys Touch, Stravix |
| Dynasplint Systems INC. | $232.11 | 2019-2023 | Dynasplint |
| Sanofi-Aventis U.S. LLC | $222.72 | 2021-2023 | |
| Depuy Synthes Sales INC. | $208.96 | 2019-2025 | Monovisc, Orthovisc |
| Sanara Medtech INC. | $200.07 | 2020-2023 | Celleraterx |
| Amgen INC. | $183.63 | 2023-2025 | Evenity, Prolia |
| Vertex Pharmaceuticals Incorporated | $177.73 | 2024-2025 | |
| Horizon Therapeutics Plc | $174.75 | 2019-2022 | |
| Osteoremedies, LLC | $155.53 | 2019 | |
| Medacta USA, INC. | $150.00 | 2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $146.27 | 2023-2025 | |
| Encore Medical, Lp | $129.87 | 2021 | |
| Zyla Life Sciences, INC. | $120.78 | 2019-2020 | |
| Zimmer Biomet Holdings, INC. | $117.37 | 2019-2024 | Tapestry, Avitus Bone Harvester |
| Pfizer INC. | $90.18 | 2020-2021 | |
| Heron Therapeutics, INC. | $90.01 | 2021-2025 | Zynrelef |
| Kci USA, INC. | $85.29 | 2020-2023 | Prevena, Prevena Restor Arthroform |
| Convatec INC. | $82.29 | 2020-2023 | |
| Solventum Corporation | $69.41 | 2024-2025 | Prevena, V.A.C.Instill, V.A.C. Veraflo Cleanse Choice |
| Bioventus LLC | $64.38 | 2019-2024 | Exogen Ultrasound Bone Healing System, Exogen Ultrasound Bone Healing System |
| Davol INC. | $50.05 | 2025 | Channel Drain |
| Ethicon US, LLC | $45.82 | 2021-2025 | Stratafix, Ethicon |
| Avanos Medical | $37.57 | 2022-2025 | Pnb and Accessories |
| Kowa Pharmaceuticals America, INC. | $37.44 | 2022-2023 | Seglentis |
| Allergan, INC. | $34.24 | 2019 | |
| Medtronic USA, INC. | $24.14 | 2019 | |
| Abbott Laboratories | $24.07 | 2021 | |
| Orthofix Medical, INC. | $23.98 | 2019-2022 | |
| Linvatec Corporation | $19.41 | 2025 | Biobrace 23mm |
| Novo Nordisk INC | $16.86 | 2023 | Wegovy |
| Baudax Bio INC. | $14.42 | 2021 | |
| Flowonix Medical Incorporated | $11.61 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $11.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Malkani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.